CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
BBRAFV600PredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaVemurafenibHyman et al., 2015
BBRAFV600PredictiveSupportsSensitivity/ResponseLangerhans-cell HistiocytosisVemurafenibHyman et al., 2015
BBRAFV600PredictiveSupportsResistanceColorectal CancerVemurafenibHyman et al., 2015
Bv::ALKFusionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaCrizotinib2015
BMETOverexpressionPredictiveDoes Not SupportResistanceSkin MelanomaVemurafenibJubb et al., 2013
BDNMT3AMutationPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaDecitabineMetzeler et al., 2012
BPOT1MUTATIONPrognosticSupportsPoor OutcomeChronic Lymphocytic LeukemiaHerling et al., 2016
BBRAFV600EPredictiveSupportsSensitivity/ResponsePapillary Thyroid CarcinomaVemurafenibBrose et al., 2016
BMKI67EXPRESSIONPrognosticSupportsPoor OutcomeProstate CancerFisher et al., 2013
DRB1Loss-of-functionPredictiveSupportsResistanceGlioblastomaPalbociclibMichaud et al., 2010
BKRASMutationPrognosticSupportsPoor OutcomePseudomyxoma PeritoneiPietrantonio et al., 2016
DCCND1AmplificationPredictiveDoes Not SupportSensitivity/ResponseOvarian CancerPalbociclibKonecny et al., 2011
DPIK3CAMutationPredictiveSupportsSensitivity/ResponseBreast CancerPalbociclib,Phosphatidylinositide 3-Kinase InhibitorVora et al., 2014
BRB1PHOSPHORYLATIONPredictiveSupportsResistanceBreast CancerAlpelisibVora et al., 2014
DPIK3CAMutationPredictiveSupportsSensitivity/ResponseBreast CancerEverolimus,MTOR Kinase Inhibitor PP242Weigelt et al., 2011
DPTENLossPredictiveDoes Not SupportSensitivity/ResponseBreast CancerEverolimus,MTOR Kinase Inhibitor PP242Weigelt et al., 2011
DPTENLossPredictiveSupportsSensitivity/ResponseEndometrial CancerTemsirolimusWeigelt et al., 2013
BCD274ExpressionPredictiveDoes Not SupportSensitivity/ResponseMelanomaIpilimumab,NivolumabWolchok et al., 2013
DPIK3CAMutationPredictiveSupportsSensitivity/ResponseEndometrial CancerPictilisibWeigelt et al., 2013
DSTK11LossPredictiveDoes Not SupportSensitivity/ResponseLung Non-small Cell CarcinomaEverolimus,SirolimusXiao et al., 2015
DPIK3CAH1047RPredictiveSupportsSensitivity/ResponseThyroid CancerPerifosine,TemsirolimusLiu et al., 2009
DPIK3CAE542KPredictiveSupportsSensitivity/ResponseThyroid CancerPerifosine,TemsirolimusLiu et al., 2009
DCCNE1AmplificationPredictiveSupportsResistanceEstrogen-receptor Positive Breast CancerPalbociclibHerrera-Abreu et al., 2016
BCDKN2ARS3814960PrognosticSupportsPoor OutcomeEsophagus Squamous Cell CarcinomaLi et al., 2016
BIDH1MutationPrognosticSupportsBetter OutcomeBrain Glioma2015, N. Engl. J. Med.
BIDH2MutationPrognosticSupportsBetter OutcomeBrain Glioma2015, N. Engl. J. Med.
BSMAD4DeletionPredictiveSupportsResistanceColorectal CancerFluorouracilBoulay et al., 2002
BTERTC228TDiagnosticSupportsPositiveThyroid CancerLiu et al., 2014
BATRXUnderexpressionPredictiveSupportsSensitivity/ResponseMalignant AstrocytomaPCV Regimen,TemozolomideWiestler et al., 2013
BAURKAOverexpressionPredictiveSupportsResistanceOvarian Serous CarcinomaPlatinum CompoundMignogna et al., 2016
BAURKAEXPRESSIONPredictiveSupportsSensitivity/ResponseEsophagus Squamous Cell CarcinomaRadiation Therapy,Cisplatin,FluorouracilTamotsu et al., 2015
BCASP8D302HPrognosticSupportsPoor OutcomeNeuroblastomaRihani et al., 2014
DGAS6EXPRESSIONPredictiveSupportsResistanceProstate CancerDocetaxelLee et al., 2016
BETV4OverexpressionPrognosticSupportsPoor OutcomeProstate CancerQi et al., 2015
CZKSCAN1::BRAFFusionPredictiveSupportsSensitivity/ResponseMelanomaTrametinibRoss et al., 2016
BEGFRL858RPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaGefitinibYang et al., 2008
BEGFRExon 19 DeletionPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaGefitinibYang et al., 2008
BEGFRT790MPredictiveSupportsResistanceLung Non-small Cell CarcinomaErlotinib,GefitinibBelchis et al., 2016
BBRAFL505HPredictiveSupportsResistanceMelanomaVemurafenibHoogstraat et al., 2015
BBRCA1MutationPrognosticSupportsBetter OutcomeOvarian CancerHarter et al., 2016
BBRCA2MutationPrognosticSupportsBetter OutcomeOvarian CancerHarter et al., 2016
BBRCA1MutationPredictiveSupportsSensitivity/ResponseOvarian CancerCediranib,OlaparibLiu et al., 2014
BBRCA2MutationPredictiveSupportsSensitivity/ResponseOvarian CancerOlaparib,CediranibLiu et al., 2014
CBRCA2D3095EPredisposingSupportsPredispositionBreast CancerPlon et al., 2008
BMLH1EXPRESSIONPrognosticSupportsPoor OutcomeStomach CarcinomaRokutan et al., 2016
BBCORMutationPrognosticSupportsBetter OutcomeStomach CancerRokutan et al., 2016
BBRCA1MutationPredictiveSupportsSensitivity/ResponseTriple-receptor Negative Breast CancerCisplatin,CarboplatinIsakoff et al., 2015
BBRCA2MutationPredictiveSupportsSensitivity/ResponseTriple-receptor Negative Breast CancerCisplatin,CarboplatinIsakoff et al., 2015
CSDC4::ROS1FusionPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaCrizotinibLe et al., 2015
Cv::ALKFusionPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaCrizotinibLe et al., 2015
Page 37 of 96
PreviousNext